DarioHealth Corp. — Form 8-K
Filed August 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
Steven Nelson, President and Chief Commercial Officer, separated from DarioHealth effective September 30, 2026 (role ended Sept 1). Company paid earned wages plus COBRA reimbursement (~$7,800 for 3 months at $2,600/month). Nelson then signed a consulting agreement effective October 1, 2026, through December 31, 2027, receiving 30,000 restricted shares vesting on first anniversary (or 15,000 immediately if terminated early), subject to Compensation Committee approval. Consulting duties include monthly strategy calls, industry insights, and introductions; Nelson retains non-compete (6 months), non-solicitation (12 months), and strict confidentiality obligations.
Why this rating
Leadership transition modest in scope—modest severance; re-engagement as consultant reduces disruption. Equity grant (30K shares) material relative to $28M market cap but vesting delayed 1+ year. Continuity through advisory role is positive; no business loss stated.
See more from August 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.